Cellectis Reveals Q2 2025 Financial Performance and Future Plans
Cellectis Unveils Second Quarter 2025 Financial Performance
NEW YORK, Aug. 4, 2025 — Cellectis (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology firm focused on developing advanced cell and gene therapies, has revealed its financial results for the second quarter of 2025, along with significant business updates. Cellectis is at the forefront of harnessing its unique gene-editing technology, aiming to provide groundbreaking solutions for challenging medical conditions.
“In an exciting development, Cellectis plans to host an Investor R&D Day in New York City. This event is set for October 16, where our leadership team will present the Phase 1 data and elaborate on the late-stage strategy for lasme-cel (UCART22) in treating relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL),” stated André Choulika, Ph.D., Cellectis’ Chief Executive Officer.
Amidst these endeavors, Cellectis has successfully completed end-of-Phase 1 reviews with the FDA and EMA for lasme-cel. The company is on schedule to launch its pivotal Phase 2 trial in the latter half of 2025, moving closer to providing innovative treatment options for patients in dire need.
Significant Pipeline Updates
Cellectis has made notable progress in its clinical pipeline. Key achievements include:
Advancements in UCART Clinical Programs
- The BALLI-01 study, evaluating lasme-cel for r/r B-ALL, has garnered attention. Following successful FDA and EMA meetings, preparations are underway for an amendment aimed at initiating a pivotal Phase 2 trial in H2 2025.
- Cellectis will unveil the Phase 1 dataset at its upcoming Investor R&D Day, further highlighting the late-stage development strategy for lasme-cel.
Focus on Eti-cel Development
- The NatHaLi-01 study for eti-cel (UCART20x22) in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) is ongoing, with a Phase 1 readout expected in late 2025.
Strategic Partnerships Enhance Growth
Cellectis is actively enhancing its collaborative efforts to broaden its research capacities:
Servier Collaboration
- An update from Allogene Therapeutics, Servier’s sublicensee, indicates a shift in the milestone timeline for an ALPHA3 clinical trial, expected now in the first half of 2026.
AstraZeneca Partnership
- Cellectis continues to work on joint research programs with AstraZeneca, covering both hematological malignancies and solid tumors, demonstrating strong collaborative strides in the field of gene and cell therapies.
Financial Overview
As of June 30, 2025, Cellectis reported cash and cash equivalents of approximately $230 million, offering a substantial financial runway into H2 2027. This positions the company well to support its clinical development and operational activities.
During the first half of 2025, consolidated revenues and other income reached $30.2 million, a significant rise from the previous year. This increase is largely driven by revenues recognized under the AstraZeneca Joint Research Collaboration Agreement.
Future Prospects
Looking ahead, Cellectis is committed to pushing the boundaries of innovation in cell and gene therapies. With robust financial backing and promising clinical trials underway, the company is poised for an impactful presence in the biotechnology sector.
Frequently Asked Questions
What are the key highlights from Cellectis’ Q2 2025 Financial Results?
Cellectis unveiled financial results demonstrating impressive growth in revenues and outlined plans to initiate pivotal Phase 2 trials for its leading candidates.
What upcoming events should investors be aware of?
An Investor R&D Day is scheduled for October 16, where critical data regarding lasme-cel will be presented.
How is Cellectis collaborating with other biotechnology firms?
Cellectis maintains strategic partnerships with both Servier and AstraZeneca, enhancing its R&D initiatives across multiple projects.
What financial position does Cellectis hold for future investments?
With $230 million in cash reserves as of June 30, 2025, Cellectis is well-equipped to fund ongoing clinical trials and expansions.
How does Cellectis plan to leverage its gene-editing technology further?
Cellectis aims to expand the use of its gene-editing platform in various therapeutic areas, emphasizing its innovative approaches in oncology.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.